Export 149 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
C. Gurgol, Foley, A., Belt, P., Denzen, E., Duffy, S., Gallagher, C., Grodman, C., Horowitz, M., Confer, D., and Carter, S., “Developing Materials for Transplant Centers to Share BMT CTN Clinical Trial Results with their Patients: A Pilot Study (Poster).”, in NCI ASCO Cancer Trials Accrual Symposium, Bethesda, MD, 2010.
A. Guimarães-Walker, Mackie, N., McMichael, A., Weber, J., McCormack, S., Cebere, I., Kay, R., Hanke, T., Dally, L., Gibiansky, L., Legg, K., DeSouza, C., Hayes, P., Gilmour, J., and Fast, P., “Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection”, 2004.
A. Guimarães-Walker, Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., Moore, S., Goonetilleke, N., and Fast, P., “Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.”, Vaccine, vol. 26, no. 51, pp. 6671-7, 2008.
D. Gu, Mao, Y., Tang, Z., Montaner, J., Shen, Z., Zhu, Q., Detels, R., Jin, X., Xiong, R., Xu, J., Ling, W., Erinoff, L., Lindblad, R., Liu, D., Van Veldhuisen, P., Hasson, A., and Wu, Z., “Loss to Follow-Up from HIV Screening to ART Initiation in Rural China.”, PLoS One, vol. 11, no. 10, p. e0164346, 2016.
J. Gryczynski, McNeely, J., Wu, L. - T., Subramaniam, G. A., Svikis, D. S., Cathers, L. A., Sharma, G., King, J., Jelstrom, E., Nordeck, C. D., Sharma, A., Mitchell, S. G., O'Grady, K. E., and Schwartz, R. P., “Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care.”, J Gen Intern Med, vol. 32, no. 9, pp. 990-996, 2017.
T. S. S. R. Group., “SCORE Study Report 5: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid f”, Archives of Ophthalmology, vol. 127, pp. 1101-1114, 2009.
“A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.”, Arch Ophthalmol, vol. 119, no. 10, pp. 1417-36, 2001.
“The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical”, Diabetes, vol. 54, no. 7, pp. 2188-97, 2005.
A. - R. Eye Diseas Group, “Risk factors associated with age-related nuclear and cortical cataract - A case-control study in the age-related eye disease study. AREDS Report No. 5”, Ophthalmology, vol. 108, pp. 1400-8, 2001.
A. - R. Eye Diseas Group, “The Age-Related Eye Disease Study: A clinical trial of zinc and antioxidants - Age-Related Eye Disease Study Report No. 2”, J Nutrition, vol. 130, p. 1516S-19S, 2000.
P. K. C. - D. R. S. Group, Aiello, L., Davis, M., Girach, A., Kles, K., Milton, R., Sheetz, M., Vignati, L., and Zhi, X., “Effect of Ruboxistaurin on Visual Loss in Patients With Diabetic Retinopathy”, Ophthalmology, vol. 113, pp. 2221-2230, 2006.
A. - R. Eye Diseas Group, Chew, E., Clemons, T. E., SanGiovanni, J. P., Danis, R., ,, Elman, M., Antoszyk, A., Ruby, A., Orth, D., Bressler, S., Fish, G., Hubbard, G., Klein, M., Chandra, S., ,, and Sperduto, R., “Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression: AREDS 2 Report Number 3”, JAMA Ophthalmol, vol. 132, pp. 142-149, 2014.
“The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4.”, Am J Ophthalmol, vol. 131, no. 2, pp. 167-75, 2001.
S. Outcomes R. Group, “Palivizumab prophylaxis of respiratory syncytial virus (RSV) - results from the 2000-2001 Synagis Outcomes Registry”, Pediatr Pulmonol, vol. 35, pp. 484-9, 2003.
A. - R. Eye Diseas Group, “The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: The Age-Related Eye Disease Study Report Number 6”, Am J Ophthalmol, vol. 132, pp. 668-81, 2001.
A. - R. Eye Diseas Group, “Design implications. AREDS Report No. 1”, Control Clin Trials, vol. 20, pp. 573-600, 1999.
T. P. K. C. - D. R. S. St Group, “The Effect of Ruboxistaurin on Visual Loss in Patients with Moderately Severe To Very Severe Nonproliferative Diabetic Retinopathy: Initial Results of The Protein Kinase C Beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical”, Diabetes, vol. 54, pp. 2188-2197, 2005.
“Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3.”, Ophthalmology, vol. 107, no. 12, pp. 2224-32, 2000.
“Studies of Pediatric Liver Transplantation (SPLIT): year 2000 outcomes.”, Transplantation, vol. 72, no. 3, pp. 463-76, 2001.
A. - R. Eye Diseas Group, “A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Age-Related Eye Disease Study Report No. 8”, Archives of Ophthalmology, vol. 119, pp. 1417-1436, 2001.
T. S. T. O. P. - R. O. P. M. Group, “Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial 1: Primary outcomes”, Pediatrics, vol. 105, pp. 295-310, 2000.
T. A. R. E. D. S. 2- H. O. M. Group, Chew, W. C., Clemons, T. E., Bressler, S. B., Elman, M. J., Danis, R. P., Domalpally, A., Heier, J. S., Kim, J. E., and Garfinkel, R., “Randomized Trial of a Home Monitoring System for Early Detection of Choroidal Neovascularization Home Monitoring of the Eye (HOME) Study”, Ophthalmology, vol. 121, pp. 535-534, 2014.
T. Age- Relate Group, Chew, E. Y., Clemons, T., SanGiovanni, J. P., Danis, R., Domalpally, A., McBee, W., Sperduto, R., and Ferris, F. L., “The Age-Related Eye Disease Study 2 (AREDS2): Study Design and Baseline Characteristics (AREDS2 Report No. 1)”, Ophthalmology, vol. 119, pp. 2282-2289, 2012.
“The Age-Related Eye Disease Study: a clinical trial of zinc and antioxidants--Age-Related Eye Disease Study Report No. 2.”, J Nutr, vol. 130, no. 5S Suppl, p. 1516S-9S, 2000.
theC. R. A. F. Study Group, “Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes”, 2003.